StemInov is a clinical stage spin-off from CHRU of Nancy and University of Lorraine that develops an off-the-shelf and allogenic cell therapy treatment in the field of inflammatory pathologies with a focus on critical care. More than a new product, our proprietary Stem cells from the Wharton jelly of umbilical cord, called WhartSep, is a new concept of immunomodulation and adaptive medicine firstly indicated and patented for the treatment of septic shock and Acute Respiratory Syndrome Disease.